Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
Clin Biochem. 2020 Nov;85:27-32. doi: 10.1016/j.clinbiochem.2020.08.005. Epub 2020 Aug 14.
Serum amyloid A (SAA) is an acute phase protein and a novel inflammatory biomarker of cardiovascular diseases. Of the four subtypes, SAA1 is the most representative biomarker. In this study, we aimed to assess the value of SAA1 as a novel biomarker for evaluating the presence and severity of acute coronary syndrome (ACS) in Chinese patients.
A total of 140 ACS patients and 88 non-ACS patients (including 36 stable coronary artery disease (SCAD) patients and 52 healthy controls) who underwent coronary angiography were enrolled. The SAA1 level was significantly higher in ACS patients compared with the SCAD and healthy control subgroups (P < 0.001, respectively), and was significantly higher in the high SYNTAX Score II (SS II) group compared with the medium SS II group and low SS II group (P < 0.001, respectively) in ACS patients. The cutoff level of SAA1 for indicating the presence of ACS was 324.65 ng/mL (sensitivity of 77.9%, specificity of 60.2% and an area under the curve of 0.717). The increased SAA1 levels were positively associated with the presence (OR = 1.013, P < 0.001) and severity (OR = 1.023, P < 0.001) of ACS. Furthermore, there was a positive correlation between SAA1 levels and SS II (r = 0.467, P < 0.001).
Our results suggest that elevated SAA1 levels may be a novel biomarker for evaluating the presence of ACS and the severity of CAD in ACS patients. Measuring SAA1 levels makes it possible to evaluate the presence of ACS and severity of CAD in ACS patients.
血清淀粉样蛋白 A（SAA）是一种急性时相蛋白，也是心血管疾病的新型炎症生物标志物。在这四种亚型中，SAA1 是最具代表性的生物标志物。本研究旨在评估 SAA1 作为一种新型生物标志物，用于评估中国患者急性冠状动脉综合征（ACS）的存在和严重程度。
共纳入 140 例 ACS 患者和 88 例非 ACS 患者（包括 36 例稳定型冠状动脉疾病（SCAD）患者和 52 例健康对照者），所有患者均接受了冠状动脉造影检查。与 SCAD 亚组和健康对照组相比，ACS 患者的 SAA1 水平显著升高（P 均<0.001），且 ACS 患者中 SYNTAX 评分 II 较高（SS II）组的 SAA1 水平显著高于中 SS II 组和低 SS II 组（P 均<0.001）。SAA1 用于指示 ACS 存在的截断值为 324.65ng/mL（灵敏度为 77.9%，特异性为 60.2%，曲线下面积为 0.717）。升高的 SAA1 水平与 ACS 的存在（OR=1.013，P<0.001）和严重程度（OR=1.023，P<0.001）呈正相关。此外，SAA1 水平与 SS II 之间呈正相关（r=0.467，P<0.001）。
我们的研究结果表明，升高的 SAA1 水平可能是评估 ACS 患者 ACS 存在和 CAD 严重程度的新型生物标志物。测量 SAA1 水平可用于评估 ACS 患者 ACS 的存在和 CAD 的严重程度。
